Juno Therapeutics Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Juno Therapeutics (JUNO) Deal Keeps It at the Cutting Edge of CAR Technology, Leerink Partners Says
May 12, 2015 7:57 AM EDTLeerink Partners Howard Liang reiterated an Outperform rating and $74 price target on Juno Therapeutics (NASDAQ: JUNO) following Q1 earnings and a deal to acquire Stage Cell Therapeutics GmbH. The deal, according to the analyst, keeps JUNO on the cutting edge of CAR Technology.
commented, "Along... More
Juno Therapeutics (JUNO) Tops Q1 EPS by 4c
May 11, 2015 4:09 PM EDTJuno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34).
Strong quarter-end cash position of$447.6 million.
Affirmed 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and now-settled litigation.
For earnings... More
Juno Therapeutics (JUNO) to Acquire German-Based Stage Cell Therapeutics for ~$59M
May 11, 2015 4:08 PM EDTJuno Therapeutics (NASDAQ: JUNO) acquired Stage Cell Therapeutics GmbH, a privately held biotechnology company based in Munich and Göttingen, Germany. The transaction furthers Juno's strategy of being a world leader in process development and the manufacturing of cellular therapies. The acquisition provides Juno access to transformative cell selection and activation capabilities, next generation manufacturing automation technologies, enhanced control of its supply chain, and lower expected long-term cost of goods. Juno plans to operate the acquired company,... More
